<div><p><b>Background: </b>Treatment of CHB with JNJ-3989 and NA &#177; JNJ-6379 has shown profound reductions in serum hepatitis B viral (HBV) markers. The INSIGHT study aims to assess intrahepatic changes in virological and immunological markers with JNJ-3989 based treatment in CHB patients.</p>

<div><p><b>Background: </b>Environmental pollutants are associated with disrupted hepatic metabolism and NAFLD. A pilot study (n=140) presented at AASLD elucidated exposures and metabolic pathways associated with NAFLD severity. To confirm these findings, a larger cross-sectional multi-‘omics study was performed in subjects with NAFLD. </p>

<div><p><b>Background: </b>Risk stratification in non-alcoholic fatty liver disease (NAFLD) using non-invasive scores including Fibrosis-4 (FIB4) and NAFLD fibrosis score (NFS) is recommended by clinical guidelines. However, FIB4 and NFS values are indeterminate in 20-50% of patients with NAFLD. We aimed to develop machine learning models to improve upon FIB4 and NFS, especially in the indeterminate-risk range.</p>

<div><p><strong><b>Background:</strong> </b><span class="NormalTextRun SCXW107492957 BCX8">Hepatitis C Virus (HCV) is a blood-borne viral pathogen resulting in hepatic inflammation that – if left untreated – may lead to advanced liver disease, hepatocellular carcinoma, and death. With the advent of improved treatment modalities, several national, state, and local governing bodies have called for HCV eradication.

<div><p><b>Background:</p> </b><p>In patients with Budd Chiari syndrome (BCS), the current treatment guidelines recommend a step-up approach starting with lifelong anticoagulation with low-molecular-weight heparin (LMWH) or vitamin K antagonists (VKA). Although direct oral anticoagulants (DOAC) may simplify patient management, there is limited data on the safety and efficacy of DOAC in patients with BCS. This study used a large research network to compare the outcomes of patients with BCS treated with DOACs, LMWH, and VKAs.</p>

<div><p><b>Background:</p> </b><div><p><span lang="EN-US">Current guidelines for the diagnosis of HRS-AKI require the use of albumin as volume expander to exclude pre-renal azotemia. The treatment of HRS-AKI (hepatorenal syndrome) also recommends the use of terlipressin with albumin at a dose of 20-40g per day. However, the optimal dose of albumin to be given in the pre- and during treatment remains unclear.

<div><p><b>Background:</p> </b><p>The mechanisms contributing to the progression to NASH in patients with NAFLD are unclear. Our central hypothesis is that the inability of hepatic mitochondria to enhance nutrient oxidation in the setting of nutrient oversupply plays a key role in the progression of liver disease in NAFLD. The aim of this study was to explore the relationship between adipose tissue insulin resistance (IR), liver fat, and <em>in vivo</em> hepatic mitochondrial function.</p>

<div><p><b>Background: </b>Human pluripotent stem cell (PSC) derived hepatocyte-like cells and primary human hepatocytes applications for clinical or research uses is dependent on the ability to generate phenotypically and functionally relevant hepatocytes or hepatocyte-containing constructs.

<div><p><strong><b>Background:</strong> </b>NCC and UCE are recommended for treatment monitoring in Wilson Disease (WD)(1). NCC is assumed to reflect the bioavailable copper (Cu) in plasma and is in equilibrium with the pool of stored Cu. UCE reflects body stores of Cu and is also influenced by the cupriuretic effect of therapy. Current methods to estimate NCC are flawed.

<div><p><b>Background:<span data-contrast="auto" xml:lang="EN-GB" lang="EN-GB" class="TextRun SCXW196881610 BCX0"> </b><span class="NormalTextRun SCXW196881610 BCX0">Following</span><span class="NormalTextRun SCXW196881610 BCX0"> </span><span class="NormalTextRun SCXW196881610 BCX0">reductions in </span><span class="NormalTextRun SCXW196881610 BCX0">steatosis and </span><span class="NormalTextRun SCXW196881610 BCX0">bod